{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T11:02:07Z","timestamp":1792839727686,"version":"4.5.0"},"reference-count":91,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2021,6,27]],"date-time":"2021-06-27T00:00:00Z","timestamp":1624752000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,6,27]],"date-time":"2021-06-27T00:00:00Z","timestamp":1624752000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharmacol. Rep"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1007\/s43440-021-00303-6","type":"journal-article","created":{"date-parts":[[2021,6,27]],"date-time":"2021-06-27T07:02:25Z","timestamp":1624777345000},"page":"1539-1550","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":114,"title":["Understanding the role of ACE-2 receptor in pathogenesis of COVID-19 disease: a potential approach for therapeutic intervention"],"prefix":"10.1007","volume":"73","author":[{"given":"Ekta","family":"Shirbhate","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaiprakash","family":"Pandey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijay K.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehnaz","family":"Kamal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Talha","family":"Jawaid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bapi","family":"Gorain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0890-769X","authenticated-orcid":false,"given":"Prashant","family":"Kesharwani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harish","family":"Rajak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,6,27]]},"reference":[{"key":"303_CR1","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1080\/21645515.2020.1735227","volume":"16","author":"K Dhama","year":"2020","unstructured":"Dhama K, Sharun K, Tiwari R, Dadar M, Malik YS, Singh KP, et al. COVID-19, an emerging coronavirus infection: advances and prospects in designing and developing vaccines, immunotherapeutics, and therapeutics. Hum Vaccines Immunother. 2020;16:1232\u20138. https:\/\/doi.org\/10.1080\/21645515.2020.1735227.","journal-title":"Hum Vaccines Immunother"},{"key":"303_CR2","doi-asserted-by":"publisher","first-page":"800","DOI":"10.3389\/FPUBH.2020.606129","volume":"8","author":"B Gorain","year":"2020","unstructured":"Gorain B, Choudhury H, Molugulu N, Athawale RB, Kesharwani P. Fighting strategies against the novel coronavirus pandemic: impact on global economy. Front Publ Health. 2020;8:800. https:\/\/doi.org\/10.3389\/FPUBH.2020.606129.","journal-title":"Front Publ Health"},{"key":"303_CR3","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1038\/s41564-020-0695-z","volume":"5","author":"AE Gorbalenya","year":"2020","unstructured":"Gorbalenya AE. The species severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming its SARS-CoV-2. Nat Microbiol. 2020;5:536\u201344. https:\/\/doi.org\/10.1038\/s41564-020-0695-z.","journal-title":"Nat Microbiol"},{"key":"303_CR4","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.ejim.2020.04.037","volume":"76","author":"P Verdecchia","year":"2020","unstructured":"Verdecchia P, Cavallini C, Spanevello A, Angeli F. The pivotal link between ACE2 deficiency and SARS-CoV-2 infection. Eur J Intern Med. 2020;76:14\u201320. https:\/\/doi.org\/10.1016\/j.ejim.2020.04.037.","journal-title":"Eur J Intern Med"},{"key":"303_CR5","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.cell.2020.02.052","volume":"181","author":"M Hoffmann","year":"2020","unstructured":"Hoffmann M, Kleine-Weber H, Schroeder S, Kr\u00fcger N, Herrler T, Erichsen S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181:280. https:\/\/doi.org\/10.1016\/j.cell.2020.02.052.","journal-title":"Cell"},{"key":"303_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2020.106192","author":"M Agrawal","year":"2020","unstructured":"Agrawal M, Saraf S, Saraf S, Murty US, Kurundkar SB, Roy D, et al. In-line treatments and clinical initiatives to fight against COVID-19 outbreak. Respir Med. 2020. https:\/\/doi.org\/10.1016\/j.rmed.2020.106192.","journal-title":"Respir Med"},{"key":"303_CR7","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1007\/s00134-020-05985-9","volume":"46","author":"H Zhang","year":"2020","unstructured":"Zhang H, Penninger JM, Li Y, Zhong N, Slutsky AS. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Med. 2020;46:586\u201390. https:\/\/doi.org\/10.1007\/s00134-020-05985-9.","journal-title":"Intensive Care Med"},{"key":"303_CR8","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.tips.2004.04.001","volume":"25","author":"AJ Turner","year":"2004","unstructured":"Turner AJ, Hiscox JA, Hooper NM. ACE2: From vasopeptidase to SARS virus receptor. Trends Pharmacol Sci. 2004;25:291\u20134. https:\/\/doi.org\/10.1016\/j.tips.2004.04.001.","journal-title":"Trends Pharmacol Sci"},{"key":"303_CR9","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1161\/CIRCRESAHA.116.307708","volume":"118","author":"VB Patel","year":"2016","unstructured":"Patel VB, Zhong JC, Grant MB, Oudit GY. Role of the ACE2\/angiotensin 1\u20137 axis of the renin-angiotensin system in heart failure. Circ Res. 2016;118:1313\u201326. https:\/\/doi.org\/10.1161\/CIRCRESAHA.116.307708.","journal-title":"Circ Res"},{"key":"303_CR10","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1101\/2020.01.26.919985","volume":"202","author":"Y Zhao","year":"2020","unstructured":"Zhao Y, Zhao Z, Wang Y, Zhou Y, Ma Y, Zuo W. Single-cell RNA expression profiling of ACE2, the putative receptor of Wuhan 2019-nCov. Am J Respir Crit Care Med. 2020;202:756\u20139. https:\/\/doi.org\/10.1101\/2020.01.26.919985.","journal-title":"Am J Respir Crit Care Med"},{"key":"303_CR11","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1097\/MNH.0000000000000182","volume":"25","author":"DI Ortiz-Melo","year":"2016","unstructured":"Ortiz-Melo DI, Gurley SB. Angiotensin converting enzyme 2 and the kidney. Curr Opin Nephrol Hypertens. 2016;25:59\u201366. https:\/\/doi.org\/10.1097\/MNH.0000000000000182.","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"303_CR12","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.cdtm.2020.05.003","volume":"6","author":"MY Liu","year":"2020","unstructured":"Liu MY, Zheng B, Zhang Y, Li JP. Role and mechanism of angiotensin-converting enzyme 2 in acute lung injury in coronavirus disease 2019. Chronic Dis Transl Med. 2020;6:98\u2013105. https:\/\/doi.org\/10.1016\/j.cdtm.2020.05.003.","journal-title":"Chronic Dis Transl Med"},{"key":"303_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/jtm\/taaa021","volume":"27","author":"Y Liu","year":"2020","unstructured":"Liu Y, Gayle AA, Wilder-Smith A, Rockl\u00f6v J. The reproductive number of COVID-19 is higher compared to SARS coronavirus. J Travel Med. 2020;27:1\u20134. https:\/\/doi.org\/10.1093\/jtm\/taaa021.","journal-title":"J Travel Med"},{"key":"303_CR14","doi-asserted-by":"publisher","first-page":"E1","DOI":"10.1161\/01.res.87.5.e1","volume":"87","author":"M Donoghue","year":"2000","unstructured":"Donoghue M, Hsieh F, Baronas E, Godbout K, Gosselin M, Stagliano N, et al. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1\u20139. Circ Res. 2000;87:E1\u20139. https:\/\/doi.org\/10.1161\/01.res.87.5.e1.","journal-title":"Circ Res"},{"key":"303_CR15","doi-asserted-by":"publisher","first-page":"33238","DOI":"10.1074\/jbc.M002615200","volume":"275","author":"SR Tipnis","year":"2000","unstructured":"Tipnis SR, Hooper NM, Hyde R, Karran E, Christie G, Turner AJ. A human homolog of angiotensin-converting enzyme: cloning and functional expression as a captopril-insensitive carboxypeptidase. J Biol Chem. 2000;275:33238\u201343. https:\/\/doi.org\/10.1074\/jbc.M002615200.","journal-title":"J Biol Chem"},{"key":"303_CR16","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/S0165-6147(00)01994-5","volume":"23","author":"AJ Turner","year":"2002","unstructured":"Turner AJ, Hooper NM. The angiotensin-converting enzyme gene family: genomics and pharmacology. Trends Pharmacol Sci. 2002;23:177\u201383. https:\/\/doi.org\/10.1016\/S0165-6147(00)01994-5.","journal-title":"Trends Pharmacol Sci"},{"key":"303_CR17","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1038\/nature00786","volume":"417","author":"MA Crackower","year":"2002","unstructured":"Crackower MA, Sarao R, Oliveira-dos-Santos AJ, Costa JD, Zhang L. Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature. 2002;417:822\u20138. https:\/\/doi.org\/10.1038\/nature00786.","journal-title":"Nature"},{"key":"303_CR18","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1152\/physrev.00023.2016","volume":"98","author":"RAS Santos","year":"2018","unstructured":"Santos RAS, Sampaio WO, Alzamora AC, Motta-Santos D, Alenina N, Bader M, et al. The ACE2\/Angiotensin-(1\u20137)\/Mas axis of the renin-angiotensin system: focus on angiotensin-(1\u20137). Physiol Rev. 2018;98:505\u201353. https:\/\/doi.org\/10.1152\/physrev.00023.2016.","journal-title":"Physiol Rev"},{"key":"303_CR19","doi-asserted-by":"publisher","first-page":"4825","DOI":"10.1111\/bph.15082","volume":"177","author":"K Sriram","year":"2020","unstructured":"Sriram K, Insel PA. A hypothesis for pathobiology and treatment of COVID-19: the centrality of ACE1\/ACE2 imbalance. Br J Pharmacol. 2020;177:4825\u201344. https:\/\/doi.org\/10.1111\/bph.15082.","journal-title":"Br J Pharmacol"},{"key":"303_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.virusres.2020.198021","volume":"285","author":"CC Giron","year":"2020","unstructured":"Giron CC, Laaksonen A, Barroso da Silva PA. On the interactions of the receptor-binding domain of SARS-CoV-1 and SARS-CoV-2 spike proteins with monoclonal antibodies and the receptor ACE2. Virus Res. 2020;285: 198021. https:\/\/doi.org\/10.1016\/j.virusres.2020.198021.","journal-title":"Virus Res"},{"key":"303_CR21","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1126\/science.abb2507","volume":"367","author":"D Wrapp","year":"2020","unstructured":"Wrapp D, Wang N, Corbett KS, Goldsmith JA, Hsieh CL, Abiona O, et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020;367:1260\u20133. https:\/\/doi.org\/10.1126\/science.abb2507.","journal-title":"Science"},{"key":"303_CR22","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.bbrc.2020.02.071","volume":"525","author":"Y Chen","year":"2020","unstructured":"Chen Y, Guo Y, Pan Y, Zhao ZJ. Structure analysis of the receptor binding of 2019-nCoV. Biochem Biophys Res Commun. 2020;525:135\u201340. https:\/\/doi.org\/10.1016\/j.bbrc.2020.02.071.","journal-title":"Biochem Biophys Res Commun"},{"key":"303_CR23","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1126\/science.abb2762","volume":"367","author":"R Yan","year":"2020","unstructured":"Yan R, Zhang Y, Li Y, Xia L, Guo Y, Zhou Q. Structural basis for the recognition of the SARS-CoV-2 by full-length human ACE2. Science. 2020;367:1444\u20138. https:\/\/doi.org\/10.1126\/science.abb2762.","journal-title":"Science"},{"key":"303_CR24","doi-asserted-by":"publisher","first-page":"820","DOI":"10.3389\/fphys.2020.00820","volume":"11","author":"FJ Barrantes","year":"2020","unstructured":"Barrantes FJ. While we wait for a vaccine against SARS-CoV-2, why not think about available drugs? Front Physiol. 2020;11:820. https:\/\/doi.org\/10.3389\/fphys.2020.00820.","journal-title":"Front Physiol"},{"key":"303_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.570018","volume":"11","author":"I Khatri","year":"2020","unstructured":"Khatri I, Stall FJT, Dongen JJMV. Blocking of the high-affinity interaction-synapse between SARS-CoV-2 spike and human ACE2 proteins likely requires multiple high-affinity antibodies: an immune perspective. Front Immunol. 2020;11: 570018. https:\/\/doi.org\/10.3389\/fimmu.2020.570018.","journal-title":"Front Immunol"},{"key":"303_CR26","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1002\/path.5471","volume":"251","author":"AR Bourgonje","year":"2020","unstructured":"Bourgonje AR, Abdulle AE, Timens W, Hillebrands JL, Navis GJ, Gordijn SJ, et al. Angiotensin-converting enzyme 2 (ACE2), SARS-CoV-2 and the pathophysiology of coronavirus disease 2019 (COVID-19). J Pathol. 2020;251:228\u201348. https:\/\/doi.org\/10.1002\/path.5471.","journal-title":"J Pathol"},{"key":"303_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.envres.2020.109819","volume":"188","author":"M Jayaweera","year":"2020","unstructured":"Jayaweera M, Perera H, Gunawardana B, Manatunge J. Transmission of COVID-19 virus by droplets and aerosols: a critical review on the unresolved dichrotomy. Environ Res. 2020;188: 109819. https:\/\/doi.org\/10.1016\/j.envres.2020.109819.","journal-title":"Environ Res"},{"key":"303_CR28","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2020.590041","volume":"8","author":"MC Jarvis","year":"2020","unstructured":"Jarvis MC. Aerosol transmission of SARS-CoV-2: physical principles and implications. Front Publ Health. 2020;8: 590041. https:\/\/doi.org\/10.3389\/fpubh.2020.590041.","journal-title":"Front Publ Health"},{"issue":"1","key":"303_CR29","doi-asserted-by":"publisher","DOI":"10.4110\/in.2021.21.e3","volume":"21","author":"G Ryu","year":"2021","unstructured":"Ryu G, Shin HW. SARS-CoV-2 infection of airway epithelial cells. Immune Netw. 2021;21(1): e3. https:\/\/doi.org\/10.4110\/in.2021.21.e3.","journal-title":"Immune Netw"},{"issue":"6","key":"303_CR30","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1016\/j.immuni.2020.05.004","volume":"52","author":"K Subbarao","year":"2020","unstructured":"Subbarao K, Mahanty S. Respiratory virus infections: understanding COVID-19. Immunity. 2020;52(6):905\u20139. https:\/\/doi.org\/10.1016\/j.immuni.2020.05.004.","journal-title":"Immunity"},{"key":"303_CR31","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1038\/s41385-020-00359-2","volume":"14","author":"O Gallo","year":"2021","unstructured":"Gallo O, Locatello LG, Mazzoni A, Novelli L, Annunziato F. The central role of the nasal microenvironment in the transmission, modulation, and clinical progression of SARS-CoV-2 infection. Mucosal Immunol. 2021;14:305\u201316. https:\/\/doi.org\/10.1038\/s41385-020-00359-2.","journal-title":"Mucosal Immunol"},{"key":"303_CR32","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1038\/s41591-020-0868-6","volume":"26","author":"W Sungnak","year":"2020","unstructured":"Sungnak W, Huang N, Becavin C, Berg M, Queen R, Litvinukova M, et al. SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes. Nat Med. 2020;26:681\u20137. https:\/\/doi.org\/10.1038\/s41591-020-0868-6.","journal-title":"Nat Med"},{"key":"303_CR33","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/cr.2008.15","volume":"18","author":"H Wang","year":"2008","unstructured":"Wang H, Yang P, Liu K, Guo F, Zhang Y, Zhang G, et al. SARS coronavirus entry into host cells through a novel clathrin- and caveolae-independent endocytic pathway. Cell Res. 2008;18:290\u2013301. https:\/\/doi.org\/10.1038\/cr.2008.15.","journal-title":"Cell Res"},{"key":"303_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2021.100306","volume":"296","author":"A Bayati","year":"2021","unstructured":"Bayati A, Kumar R, Francis V, McPherson P. SARS-CoV-2 infects cells following viral entry via clathrin-mediated endocytosis. J Biol Chem. 2021;296: 100306. https:\/\/doi.org\/10.1016\/j.jbc.2021.100306.","journal-title":"J Biol Chem"},{"key":"303_CR35","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1038\/s41565-020-0674-9","volume":"15","author":"TY Hu","year":"2020","unstructured":"Hu TY, Frieman M, Wolfram J. Insights from nanomedicine into chloroquine efficacy against COVID-19. Nat Nanotechnol. 2020;15:247\u20139. https:\/\/doi.org\/10.1038\/s41565-020-0674-9.","journal-title":"Nat Nanotechnol"},{"key":"303_CR36","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1080\/22221751.2020.1746199","volume":"9","author":"L Lin","year":"2020","unstructured":"Lin L, Lu L, Cao W, Li T. Hypothesis for potential pathogenesis of SARS-CoV-2 infection\u2014a review of immune changes in patients with viral pneumonia. Emerg Microbes Infect. 2020;9:727\u201332. https:\/\/doi.org\/10.1080\/22221751.2020.1746199.","journal-title":"Emerg Microbes Infect"},{"key":"303_CR37","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/S0140-6736(20)30566-3","volume":"395","author":"F Zhou","year":"2020","unstructured":"Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395:1054\u201362. https:\/\/doi.org\/10.1016\/S0140-6736(20)30566-3.","journal-title":"Lancet"},{"key":"303_CR38","doi-asserted-by":"publisher","first-page":"372","DOI":"10.3390\/v12040372","volume":"12","author":"Y Jin","year":"2020","unstructured":"Jin Y, Yang H, Ji W, Wu W, Chen S, Zhang W, et al. Virology, epidemiology, pathogenesis, and control of covid-19. Viruses. 2020;12:372. https:\/\/doi.org\/10.3390\/v12040372.","journal-title":"Viruses"},{"issue":"2","key":"303_CR39","first-page":"108","volume":"19","author":"H Mohammadpour","year":"2020","unstructured":"Mohammadpour H, Ziai A, Sadr M, Rezaei M, Marjani M, Tabarsi P. A novel coronavirus disease (COVID-19): a review of host cell signaling pathways. Tanaffos. 2020;19(2):108\u201311 (PMID: 33262797).","journal-title":"Tanaffos"},{"key":"303_CR40","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.tim.2020.12.007","volume":"29","author":"RK Suryawanshi","year":"2021","unstructured":"Suryawanshi RK, Koganti R, Agelidis A, Patil CD, Shukla D. Dysregulation of cell signaling by SARS-CoV-2. Trends Microbiol. 2021;29:224\u201337. https:\/\/doi.org\/10.1016\/j.tim.2020.12.007.","journal-title":"Trends Microbiol"},{"key":"303_CR41","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1007\/s00408-020-00408-4","volume":"198","author":"F Scialo","year":"2020","unstructured":"Scialo F, Daniele A, Amato F, Pastore L, Matera MG, Cazzola M, et al. The major cell entry receptor for SARS-CoV-2. Lungs. 2020;198:867\u201377. https:\/\/doi.org\/10.1007\/s00408-020-00408-4.","journal-title":"Lungs"},{"issue":"3","key":"303_CR42","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1007\/s00705-021-04958-7","volume":"166","author":"N Hemmat","year":"2021","unstructured":"Hemmat N, Asadzadeh Z, Ahangar NK, Alemohammad H, Najafzadeh B, Derakhshani A, et al. The roles of signaling pathways in SARS-CoV-2 infection; lessons learned from SARS-CoV and MERS-CoV. Arch Virol. 2021;166(3):675\u201396. https:\/\/doi.org\/10.1007\/s00705-021-04958-7.","journal-title":"Arch Virol"},{"key":"303_CR43","doi-asserted-by":"publisher","DOI":"10.1097\/MD.000000000002432","volume":"100","author":"C Li-Chin","year":"2021","unstructured":"Li-Chin C, Tzu-Jen K, Nam Nhut P, Chung-Chieh C, Meng-Chi Y, Chien-Fu C, et al. Novel signaling pathways regulate SARS-CoV and SARS-CoV-2 infectious disease. Medicine. 2021;100: e24321. https:\/\/doi.org\/10.1097\/MD.000000000002432.","journal-title":"Medicine"},{"key":"303_CR44","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1042\/CS20200904","volume":"134","author":"DS Battagello","year":"2020","unstructured":"Battagello DS, Dragunas G, Klein MO, Ayub ALP, Velloso FJ, Correa RG. Unpuzzling COVID-19: tissue-related signaling pathways associated with SARS-CoV-2 infection and transmission. Clin Sci (Lond). 2020;134:2137\u201360. https:\/\/doi.org\/10.1042\/CS20200904.","journal-title":"Clin Sci (Lond)"},{"key":"303_CR45","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1038\/s41401-020-0485-4","volume":"41","author":"Y Huang","year":"2020","unstructured":"Huang Y, Yang C, Xu XF, Xu W, Liu SW. Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19. Acta Pharmacol Sin. 2020;41:1141\u20139. https:\/\/doi.org\/10.1038\/s41401-020-0485-4.","journal-title":"Acta Pharmacol Sin"},{"key":"303_CR46","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","volume":"181","author":"M Hoffmann","year":"2020","unstructured":"Hoffmann M, Kleine-Weber H, Schroeder S, Kruger N, Herrler T, Erichsen S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181:271-80.e8. https:\/\/doi.org\/10.1016\/j.cell.2020.02.052.","journal-title":"Cell"},{"key":"303_CR47","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1515\/cclm-2020-0727","volume":"58","author":"G Lippi","year":"2020","unstructured":"Lippi G, Lavie CJ, Henry BM, Sanchis-Gomar F. Do genetic polymorphisms in angiotensin converting enzyme 2 (ACE2) gene play a role in coronavirus disease 2019 (COVID-19)? Clin Chem Lab Med. 2020;58:1415\u201322. https:\/\/doi.org\/10.1515\/cclm-2020-0727.","journal-title":"Clin Chem Lab Med"},{"key":"303_CR48","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1161\/HYPERTENSIONAHA.120.15256","volume":"76","author":"AM Davidson","year":"2020","unstructured":"Davidson AM, Wysocki J, Batlle D. Interaction of SARS-CoV-2 and other coronavirus with ACE (Angiotensin-Converting Enzyme)-2 as their main receptor: therapeutic implications. Hypertension. 2020;76:1339\u201349. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.120.15256.","journal-title":"Hypertension"},{"key":"303_CR49","doi-asserted-by":"publisher","first-page":"4541","DOI":"10.1038\/s41467-020-18319-6","volume":"11","author":"J Yang","year":"2020","unstructured":"Yang J, Petitjean SJL, Koehler M, Zhang Q, Dumitru AC, Chen W, et al. Molecular interaction and inhibition of SARS-CoV-2 binding to the ACE2 receptor. Nat Commun. 2020;11:4541. https:\/\/doi.org\/10.1038\/s41467-020-18319-6.","journal-title":"Nat Commun"},{"key":"303_CR50","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2020.591873","volume":"7","author":"Y Xie","year":"2020","unstructured":"Xie Y, Karki CB, Du D, Li H, Wang J, Sobitan A, Teng S, et al. Spike proteins of SARS-CoV and SARS-CoV-2 utilize different mechanisms to bind with human ACE2. Front Mol Biosci. 2020;7: 591873. https:\/\/doi.org\/10.3389\/fmolb.2020.591873.","journal-title":"Front Mol Biosci"},{"key":"303_CR51","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1038\/s41423-020-0400-4","volume":"17","author":"W Tai","year":"2020","unstructured":"Tai W, He L, Zhang X, Pu J, Voronin D, Jiang S, et al. Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine. Cell Mol Immunol. 2020;17:613\u201320. https:\/\/doi.org\/10.1038\/s41423-020-0400-4.","journal-title":"Cell Mol Immunol"},{"key":"303_CR52","doi-asserted-by":"publisher","first-page":"497","DOI":"10.3390\/v12050497","volume":"12","author":"ES Brielle","year":"2020","unstructured":"Brielle ES, Schneidman-Duhovny D, Linial M. The SARS-CoV-2 exerts a distinctive strategy for interacting with the ACE2 human receptor. Viruses. 2020;12:497. https:\/\/doi.org\/10.3390\/v12050497.","journal-title":"Viruses"},{"key":"303_CR53","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.ihj.2020.04.007","volume":"72","author":"S Bansal","year":"2020","unstructured":"Bansal S, Agstam S, Gupta A, Gupta P, Isser HS. Continue ACE inhibitors\/ARB\u2019S till further evidence in coronavirus disease 2019 (COVID-19). Indian Heart J. 2020;72:212\u20133. https:\/\/doi.org\/10.1016\/j.ihj.2020.04.007.","journal-title":"Indian Heart J"},{"key":"303_CR54","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1186\/s13054-020-03120-0","volume":"24","author":"W Ni","year":"2020","unstructured":"Ni W, Yang X, Yang D, Bao J, Li R, Xiao Y, et al. Role of angiotensin-converting enzyme 2 (ACE2) in COVID-19. Crit Care. 2020;24:422. https:\/\/doi.org\/10.1186\/s13054-020-03120-0.","journal-title":"Crit Care"},{"key":"303_CR55","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/nature03712","volume":"436","author":"Y Imai","year":"2005","unstructured":"Imai Y, Kuba K, Rao S, Huan Y, Guo F, Guan B, et al. Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature. 2005;436:112\u20136. https:\/\/doi.org\/10.1038\/nature03712.","journal-title":"Nature"},{"key":"303_CR56","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1038\/nm1267","volume":"11","author":"K Kuba","year":"2005","unstructured":"Kuba K, Imai Y, Rao S, Gao H, Guo F, Guan B, et al. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nat Med. 2005;11:875\u20139. https:\/\/doi.org\/10.1038\/nm1267.","journal-title":"Nat Med"},{"key":"303_CR57","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1002\/path.1570","volume":"203","author":"I Hamming","year":"2004","unstructured":"Hamming I, Timens W, Bulthuis MLC, Lely AT, Navis GJ, Goor HV. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol. 2004;203:631\u20137. https:\/\/doi.org\/10.1002\/path.1570.","journal-title":"J Pathol"},{"key":"303_CR58","doi-asserted-by":"publisher","first-page":"3025","DOI":"10.1172\/JCI68782","volume":"123","author":"CE Barkauskas","year":"2013","unstructured":"Barkauskas CE, Cronce MJ, Rackley CR, Bowie EJ, Keene DR, Stripp BR, et al. Type 2 alveolar cells are stem cells in adult lung. J Clin Invest. 2013;123:3025\u201336. https:\/\/doi.org\/10.1172\/JCI68782.","journal-title":"J Clin Invest"},{"key":"303_CR59","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2020.102536","volume":"19","author":"F Rivellese","year":"2020","unstructured":"Rivellese F, Prediletto E. ACE2 at the centre of COVID-19 from paucisymptomatic infections to severe pneumonia. Autoimmun Rev. 2020;19: 102536. https:\/\/doi.org\/10.1016\/j.autrev.2020.102536.","journal-title":"Autoimmun Rev"},{"key":"303_CR60","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1186\/s13054-017-1882-z","volume":"21","author":"H Zhang","year":"2017","unstructured":"Zhang H, Baker A. Recombinant human ACE2: acing out angiotensin II in ARDS therapy. Crit Care. 2017;21:305. https:\/\/doi.org\/10.1186\/s13054-017-1882-z.","journal-title":"Crit Care"},{"key":"303_CR61","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.120.016219","volume":"9","author":"J Guo","year":"2020","unstructured":"Guo J, Huang Z, Lin L, Lv J. Coronavirus Disease 2019 (COVID-19) and cardiovascular disease: a viewpoint on the potential influence of angiotensin-converting enzyme inhibitors\/angiotensin receptor blockers on onset and severity of severe acute respiratory syndrome coronavirus 2 Infection. J Am Heart Assoc. 2020;9: e016219. https:\/\/doi.org\/10.1161\/JAHA.120.016219.","journal-title":"J Am Heart Assoc"},{"key":"303_CR62","doi-asserted-by":"publisher","unstructured":"Colafella KMM, Uijl E, Danser AHJ. Interference with the renin-angiotensin system (RAS): classical inhibitors and novel approaches. In: Encycl Endocr Dis. Elsevier; 2018. p. 523\u201330. https:\/\/doi.org\/10.1016\/B978-0-12-801238-3.65341-2.","DOI":"10.1016\/B978-0-12-801238-3.65341-2"},{"key":"303_CR63","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1186\/s13054-017-1823-x","volume":"21","author":"A Khan","year":"2017","unstructured":"Khan A, Benthin C, Zeno B, Albertson TE, Boyd J, Christie JD, et al. A pilot clinical trial of recombinant human angiotensin-converting enzyme 2 in acute respiratory distress syndrome. Crit Care. 2017;21:234. https:\/\/doi.org\/10.1186\/s13054-017-1823-x.","journal-title":"Crit Care"},{"key":"303_CR64","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1002\/jmv.24736","volume":"89","author":"AA Elfiky","year":"2017","unstructured":"Elfiky AA, Mahdy SM, Elshemey WM. Quantitative structure-activity relationship and molecular docking revealed a potency of anti-hepatitis C virus drugs against human corona viruses. J Med Virol. 2017;89:1040\u20137. https:\/\/doi.org\/10.1002\/jmv.24736.","journal-title":"J Med Virol"},{"key":"303_CR65","doi-asserted-by":"publisher","first-page":"8017","DOI":"10.1128\/jvi.00998-13","volume":"87","author":"AO Adedeji","year":"2013","unstructured":"Adedeji AO, Severson W, Jonsson C, Singh K, Weiss SR, Sarafianos SG. Novel inhibitors of severe acute respiratory syndrome coronavirus entry that act by three distinct mechanisms. J Virol. 2013;87:8017\u201328. https:\/\/doi.org\/10.1128\/jvi.00998-13.","journal-title":"J Virol"},{"key":"303_CR66","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m2710","volume":"370","author":"R Ting","year":"2020","unstructured":"Ting R, Edmonds P, Higginson IJ, Sleeman KE. Palliative care for patients with severe COVID-19. BMJ. 2020;370: m2710. https:\/\/doi.org\/10.1136\/bmj.m2710.","journal-title":"BMJ"},{"key":"303_CR67","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1007\/s42399-020-00341-w","volume":"2","author":"GM Bwire","year":"2020","unstructured":"Bwire GM. Coronavirus: why men are more vulnerable to COVID-19 than women? SN Compr Clin Med. 2020;2:874\u20136. https:\/\/doi.org\/10.1007\/s42399-020-00341-w.","journal-title":"SN Compr Clin Med"},{"key":"303_CR68","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/j.tjog.2020.09.004","volume":"59","author":"WH Chang","year":"2020","unstructured":"Chang WH. Understanding the COVID-19 pandemic from a gender perspective. Taiwan J Obstet Gynecol. 2020;59:801\u20137. https:\/\/doi.org\/10.1016\/j.tjog.2020.09.004.","journal-title":"Taiwan J Obstet Gynecol"},{"key":"303_CR69","doi-asserted-by":"publisher","first-page":"3474","DOI":"10.3390\/ijms21103474","volume":"21","author":"D Gemmati","year":"2020","unstructured":"Gemmati D, Bramanti B, Serino ML, Secchiero P, Zauli P, Tisato V. COVID-19 and individual genetic susceptibility\/receptivity: Role of ACE1\/ACE2 genes, immunity, inflammation and coagulation might the double x-chromosome in females be protective against SARS-COV-2 compared to the single x-chromosome in males? Int J Mol Sci. 2020;21:3474. https:\/\/doi.org\/10.3390\/ijms21103474.","journal-title":"Int J Mol Sci"},{"key":"303_CR70","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1016\/j.hlc.2020.05.004","volume":"29","author":"RH Arnold","year":"2020","unstructured":"Arnold RH. COVID-19\u2014does this disease kill due to imbalance of the renin angiotensin system (RAS) caused by genetic and gender differences in the response to viral ACE 2 attack? Heart Lung Circ. 2020;29:964\u201372. https:\/\/doi.org\/10.1016\/j.hlc.2020.05.004.","journal-title":"Heart Lung Circ"},{"key":"303_CR71","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1038\/ajh.2011.188","volume":"25","author":"SK Patel","year":"2012","unstructured":"Patel SK, Wai B, Ord M, MacIsaac RJ, Grant S, Velkoska E, et al. Association of ACE2 genetic variants with blood pressure, left ventricular mass, and cardiac function in caucasians with type 2 diabetes. Am J Hypertens. 2012;25:216\u201322. https:\/\/doi.org\/10.1038\/ajh.2011.188.","journal-title":"Am J Hypertens"},{"key":"303_CR72","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1038\/s41440-018-0166-6","volume":"42","author":"Y Luo","year":"2019","unstructured":"Luo Y, Liu C, Guan T, Li Y, Lai Y, Li F, et al. Association of ACE2 genetic polymorphisms with hypertension-related target organ damages in south Xinjiang. Hypertens Res. 2019;42:681\u20139. https:\/\/doi.org\/10.1038\/s41440-018-0166-6.","journal-title":"Hypertens Res"},{"key":"303_CR73","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1007\/s11427-020-1643-8","volume":"63","author":"Y Liu","year":"2020","unstructured":"Liu Y, Yang Y, Zhang C, Huang F, Wang F, Yuan J, et al. Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury. Sci China Life Sci. 2020;63:364\u201374. https:\/\/doi.org\/10.1007\/s11427-020-1643-8.","journal-title":"Sci China Life Sci"},{"key":"303_CR74","doi-asserted-by":"publisher","first-page":"145","DOI":"10.2217\/fvl.10.4","volume":"5","author":"BA Wevers","year":"2010","unstructured":"Wevers BA, Hoek LVD. Renin-angiotensin system in human coronavirus pathogenesis. Future Virol. 2010;5:145\u201361. https:\/\/doi.org\/10.2217\/fvl.10.4.","journal-title":"Future Virol"},{"key":"303_CR75","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1002\/ddr.21656","volume":"81","author":"D Gurwitz","year":"2020","unstructured":"Gurwitz D. Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics. Drug Dev Res. 2020;81:537\u201340. https:\/\/doi.org\/10.1002\/ddr.21656.","journal-title":"Drug Dev Res"},{"key":"303_CR76","doi-asserted-by":"publisher","first-page":"134","DOI":"10.31486\/toj.20.0056","volume":"20","author":"A Lowe","year":"2020","unstructured":"Lowe A, Chang DD, Creek G. Multipte fatalities in a family cluster of COVID-19 with acute respiratory distress syndrome. Ochsner J. 2020;20:134\u20138. https:\/\/doi.org\/10.31486\/toj.20.0056.","journal-title":"Ochsner J"},{"key":"303_CR77","doi-asserted-by":"publisher","first-page":"271","DOI":"10.3389\/fmolb.2020.588618","volume":"7","author":"F Saponaro","year":"2020","unstructured":"Saponaro F, Rutigliano G, Sestito S, Bandini L, Storti B, Bizzarri R, et al. ACE2 in the era of SARS-CoV-2: controversies and novel perspectives. Front Mol Biosci. 2020;7:271. https:\/\/doi.org\/10.3389\/fmolb.2020.588618.","journal-title":"Front Mol Biosci"},{"key":"303_CR78","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1038\/s41440-020-00560-7","volume":"44","author":"H Okamoto","year":"2020","unstructured":"Okamoto H, Ichikawa N. The pivotal role of the angiotensin-II\u2013NF-\u03baB axis in the development of COVID-19 pathophysiology. Hypertens Res. 2020;44:126\u20138. https:\/\/doi.org\/10.1038\/s41440-020-00560-7.","journal-title":"Hypertens Res"},{"key":"303_CR79","doi-asserted-by":"publisher","first-page":"603736","DOI":"10.3389\/fphar.2021.603736","volume":"12","author":"RP Rothlin","year":"2021","unstructured":"Rothlin RP, Duarte M, Pelorosso FG, Nicolosi L, Salgado MV, Vetulli HM, et al. Angiotensin receptor blockers for COVID-19: pathophysiological and pharmacological considerations about ongoing and guture prospective clinical trials. Front Pharmacol. 2021;12:603736.","journal-title":"Front Pharmacol"},{"key":"303_CR80","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1056\/NEJM200005043421806","volume":"342","author":"LB Ware","year":"2000","unstructured":"Ware LB, Matthay MA. The acute respiratory distress syndrome. N Engl J Med. 2000;342:1334\u201349. https:\/\/doi.org\/10.1056\/NEJM200005043421806.","journal-title":"N Engl J Med"},{"key":"303_CR81","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1038\/76897","volume":"1","author":"T Nagase","year":"2000","unstructured":"Nagase T, Uozumi N, Ishii S, Kume K, Izumi T, Ouchi Y, et al. Acute lung injury by sepsis and acid aspiration: a key role for cytosolic phospholipase A2. Nat Immunol. 2000;1:42\u20135. https:\/\/doi.org\/10.1038\/76897.","journal-title":"Nat Immunol"},{"key":"303_CR82","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1164\/rccm.2108086","volume":"166","author":"RP Marshall","year":"2002","unstructured":"Marshall RP, Webb S, Bellingan GJ, Montgomery HE, Chaudhari B, McAnulty RJ, et al. Angiotensin converting enzyme insertion\/deletion polymorphism is associated with susceptibility and outcome in acute respiratory distress syndrome. Am J Respir Crit Care Med. 2002;166:646\u201350. https:\/\/doi.org\/10.1164\/rccm.2108086.","journal-title":"Am J Respir Crit Care Med"},{"key":"303_CR83","doi-asserted-by":"publisher","first-page":"9530","DOI":"10.1073\/pnas.0510232103","volume":"103","author":"TY Ling","year":"2006","unstructured":"Ling TY, Kuo MD, Li CL, Yu AL, Huang YH, Wu TJ, et al. Identification of pulmonary Oct-4+ stem\/progenitor cells and demonstration of their susceptibility to SARS coronavirus (SARS-CoV) infection in vitro. Proc Natl Acad Sci USA. 2006;103:9530\u20135. https:\/\/doi.org\/10.1073\/pnas.0510232103.","journal-title":"Proc Natl Acad Sci USA"},{"key":"303_CR84","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1016\/j.apsb.2020.04.013","volume":"10","author":"J Bian","year":"2020","unstructured":"Bian J, Zhao R, Zhai S, Li Z. Anti-RAS drugs and SARS-CoV-2 infection. Acta Pharm Sin B. 2020;10:1251\u20132. https:\/\/doi.org\/10.1016\/j.apsb.2020.04.013.","journal-title":"Acta Pharm Sin B"},{"key":"303_CR85","doi-asserted-by":"publisher","first-page":"113","DOI":"10.3126\/ajms.v11i6.29911","volume":"11","author":"TI Hariyanto","year":"2020","unstructured":"Hariyanto TI, Japar KV, Damay V, Kwenandar F, Sieto NL, Kurniawan A. The use of ACE inhibitor\/ARB in SARS-CoV-2 patients: a comprehensive narrative review. Asian J Med Sci. 2020;11:113\u201320. https:\/\/doi.org\/10.3126\/ajms.v11i6.29911.","journal-title":"Asian J Med Sci"},{"key":"303_CR86","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1097\/CCM.0b013e3181c03009","volume":"38","author":"B Treml","year":"2010","unstructured":"Treml B, Neu N, Kleinsasser A, Gritsch C, Finsterwalder T, Geiger R, et al. Recombinant angiotensin-converting enzyme 2 improves pulmonary blood flow and oxygenation in lipopolysaccharide-induced lung injury in piglets. Crit Care Med. 2010;38:596\u2013601. https:\/\/doi.org\/10.1097\/CCM.0b013e3181c03009.","journal-title":"Crit Care Med"},{"key":"303_CR87","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1016\/j.cell.2020.04.004","volume":"181","author":"V Monteil","year":"2020","unstructured":"Monteil V, Kwon H, Prado P, Hagelkr\u00fcys A, Wimmer RA, Stahl M, et al. Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2. Cell. 2020;181:905-913.e7. https:\/\/doi.org\/10.1016\/j.cell.2020.04.004.","journal-title":"Cell"},{"key":"303_CR88","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1007\/s40262-013-0072-7","volume":"52","author":"M Haschke","year":"2013","unstructured":"Haschke M, Schuster M, Poglitsch M, Loibner H, Salzberg M, Bruggisser M, et al. Pharmacokinetics and pharmacodynamics of recombinant human angiotensin-converting enzyme 2 in healthy human subjects. Clin Pharmacokinet. 2013;52:783\u201392. https:\/\/doi.org\/10.1007\/s40262-013-0072-7.","journal-title":"Clin Pharmacokinet"},{"key":"303_CR89","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1164\/rccm.201205-0880OC","volume":"187","author":"V Shenoy","year":"2013","unstructured":"Shenoy V, Gjymishka A, Jarajapu YP, Qi Y, Afzal A, Rigatto K, et al. Diminazene attenuates pulmonary hypertension and improves angiogenic progenitor cell functions in experimental models. Am J Respir Crit Care Med. 2013;187:648\u201357. https:\/\/doi.org\/10.1164\/rccm.201205-0880OC.","journal-title":"Am J Respir Crit Care Med"},{"key":"303_CR90","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1053\/j.jvca.2020.04.010","volume":"34","author":"JGT Augoustides","year":"2020","unstructured":"Augoustides JGT. The renin-angiotensin-aldosterone system in coronavirus infection-current considerations during the pandemic. J Cardiothorac Vasc Anesth. 2020;34:1717\u20139. https:\/\/doi.org\/10.1053\/j.jvca.2020.04.010.","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"303_CR91","doi-asserted-by":"publisher","first-page":"39808","DOI":"10.1039\/d0ra08228g","volume":"10","author":"B Chatterjee","year":"2020","unstructured":"Chatterjee B, Thakur SS. ACE2 as a potential therapeutic target for pandemic COVID-19. RSC Adv. 2020;10:39808\u201313. https:\/\/doi.org\/10.1039\/d0ra08228g.","journal-title":"RSC Adv"}],"container-title":["Pharmacological Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43440-021-00303-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s43440-021-00303-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43440-021-00303-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,18]],"date-time":"2021-11-18T05:17:03Z","timestamp":1637212623000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s43440-021-00303-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,27]]},"references-count":91,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["303"],"URL":"https:\/\/doi.org\/10.1007\/s43440-021-00303-6","relation":{},"ISSN":["1734-1140","2299-5684"],"issn-type":[{"value":"1734-1140","type":"print"},{"value":"2299-5684","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,27]]},"assertion":[{"value":"22 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"There is no conflict of interest and disclosures associated with the manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}